Literature DB >> 33578899

Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries.

Marat V Ezhov1, Narek A Tmoyan1, Olga I Afanasieva2, Marina I Afanasieva2, Sergei N Pokrovsky2.   

Abstract

BACKGROUND: Despite high-intensity lipid-lowering therapy, there is a residual risk of cardiovascular events that could be associated with lipoprotein(a) (Lp(a)). It has been shown that there is an association between elevated Lp(a) level and cardiovascular outcomes in patients with coronary heart disease. Data about the role of Lp(a) in the development of cardiovascular events after peripheral revascularization are scarce.
PURPOSE: To evaluate the relationship of Lp(a) level with cardiovascular outcomes after revascularization of carotid and lower limbs arteries.
METHODS: The study included 258 patients (209 men, mean age 67 years) with severe carotid and/or lower extremity artery disease, who underwent successful elective peripheral revascularization. The primary endpoint was the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. The secondary endpoint was the composite of primary endpoint and repeated revascularization.
RESULTS: For 36-month follow-up, 29 (11%) primary and 128 (50%) secondary endpoints were registered. There was a greater risk of primary (21 (8%) vs. 8 (3%); hazard ratio (HR), 3.0; 95% confidence interval (CI) 1.5-6.3; p < 0.01) and secondary endpoints (83 (32%) vs. 45 (17%), HR, 2.8; 95% CI 2.0-4.0; p < 0.01) in patients with elevated Lp(a) level (≥30 mg/dL) compared to patients with Lp(a) < 30 mg/dL. Multivariable-adjusted Cox regression analysis revealed that Lp(a) was independently associated with the incidence of cardiovascular outcomes.
CONCLUSIONS: Patients with peripheral artery diseases have a high risk of cardiovascular events. Lp(a) level above 30 mg/dL is significantly and independently associated with cardiovascular events during 3-year follow-up after revascularization of carotid and lower limbs arteries.

Entities:  

Keywords:  atherosclerosis; cardiovascular disease; cardiovascular events; carotid artery disease; carotid atherosclerosis; lipoprotein(a); peripheral artery disease

Mesh:

Substances:

Year:  2021        PMID: 33578899      PMCID: PMC7916698          DOI: 10.3390/biom11020257

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  26 in total

1.  Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting.

Authors:  Marat V Ezhov; Maya S Safarova; Olga I Afanasieva; Valery V Kukharchuk; Sergei N Pokrovsky
Journal:  Atherosclerosis       Date:  2014-06-04       Impact factor: 5.162

2.  Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

Review 3.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

4.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).

Authors:  Marc P Bonaca; Patrice Nault; Robert P Giugliano; Anthony C Keech; Armando Lira Pineda; Estella Kanevsky; Julia Kuder; Sabina A Murphy; J Wouter Jukema; Basil S Lewis; Lale Tokgozoglu; Ransi Somaratne; Peter S Sever; Terje R Pedersen; Marc S Sabatine
Journal:  Circulation       Date:  2017-11-13       Impact factor: 29.690

Review 5.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

6.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.

Authors:  Deepak L Bhatt; Kim A Eagle; E Magnus Ohman; Alan T Hirsch; Shinya Goto; Elizabeth M Mahoney; Peter W F Wilson; Mark J Alberts; Ralph D'Agostino; Chiau-Suong Liau; Jean-Louis Mas; Joachim Röther; Sidney C Smith; Geneviève Salette; Charles F Contant; Joseph M Massaro; Ph Gabriel Steg
Journal:  JAMA       Date:  2010-08-30       Impact factor: 56.272

7.  Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.

Authors:  Kausik K Ray; Antonio J Vallejo-Vaz; Henry N Ginsberg; Michael H Davidson; Michael J Louie; Maja Bujas-Bobanovic; Pascal Minini; Robert H Eckel; Christopher P Cannon
Journal:  Atherosclerosis       Date:  2019-06-08       Impact factor: 5.162

8.  Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.

Authors:  Paul J Nestel; Elizabeth H Barnes; Andrew M Tonkin; John Simes; Marion Fournier; Harvey D White; David M Colquhoun; Stefan Blankenberg; David R Sullivan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-03       Impact factor: 8.311

9.  Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States.

Authors:  Steve Varvel; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-22       Impact factor: 8.311

10.  Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

Authors:  Amit V Khera; Brendan M Everett; Michael P Caulfield; Feras M Hantash; Jay Wohlgemuth; Paul M Ridker; Samia Mora
Journal:  Circulation       Date:  2013-11-17       Impact factor: 29.690

View more
  1 in total

1.  Is Lipoprotein(a) the Most Important Predictor of Residual Atherosclerotic Cardiovascular Disease Risk?

Authors:  Nathan D Wong
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.